Treatment of Esophagitis

Erosive Esophagitis (GERD-Related)

• The American College of Gastroenterology recommends PPIs as first-line therapy for erosive esophagitis, with healing rates exceeding 80% after 8 weeks of treatment in most patients 1
• Long-term daily PPI therapy is strongly recommended for patients with healed erosive esophagitis to prevent recurrence, as recurrence rates are extremely high when PPIs are discontinued 1
• On-demand or intermittent PPI dosing is NOT recommended for patients with a history of erosive esophagitis, as recurrence rates of erosive disease are unacceptably high compared to continuous therapy 1
• For PPI-refractory erosive esophagitis, consider higher doses or twice-daily dosing before endoscopic evaluation 1

Eosinophilic Esophagitis (EoE)

• The American Gastroenterological Association recommends topical corticosteroids as first-line treatment due to high efficacy in achieving both clinical and histological remission 2
• PPIs should be considered as a potential early or initial treatment for EoE due to low cost, good safety profile, convenience, and substantial evidence of efficacy 3, 4, 2
• A six-food elimination diet is effective, with higher histological remission rates than two or four food elimination diets 2
• Endoscopic dilation is effective for improving dysphagia in patients with strictures, using either balloon or bougie dilators 2
• After initiation of therapy, endoscopy with biopsy while on treatment is recommended to assess response, as symptoms may not correlate with histological activity 2, 5

Infectious Esophagitis

• The Infectious Diseases Society of America recommends systemic antifungal therapy for effective treatment of candidal esophagitis 6
• A 14-21 day course of either fluconazole or itraconazole solution is highly effective for treating candidal esophagitis 6

Common Pitfalls and Caveats

• Do not assume symptom resolution equals histological healing in EoE—endoscopic assessment is necessary 2, 5
• Avoid on-demand PPI therapy in patients with documented erosive esophagitis—continuous therapy is required to prevent recurrence 1
• Do not overlook coexisting GERD and EoE—some patients require treatment for both conditions simultaneously 3, 4

Management of Esophagitis

Eosinophilic Esophagitis (EoE) Treatment

• Endoscopic dilation (balloon or bougie) is effective and safe for improving dysphagia in patients with strictures, and should be combined with anti-inflammatory therapy for optimal outcomes 7
• For patients achieving histological response, continuation of PPIs or topical corticosteroids is recommended, as relapse rates are high after withdrawal 7
• Long-term maintenance therapy prevents recurrent dysphagia, food impaction, and esophageal stricture formation 7

Infectious Esophagitis (Immunocompromised Patients) Diagnosis and Treatment

• HIV-positive patients with esophageal symptoms may be treated empirically with antifungal therapy without initial diagnostic examination, and patients with severe symptoms at presentation or persistent symptoms should undergo endoscopy for specimen acquisition 8
• Biphasic esophagram is more accurate than single-contrast esophagram for detecting ulcers or plaques associated with infectious esophagitis, and endoscopy is preferred when available due to ability to obtain specimens for histology, cytology, immunostaining, or culture 8
• Patients with radiographically diagnosed herpes esophagitis may be treated with antiviral agents without endoscopic evaluation, but endoscopy is warranted for patients with giant esophageal ulcers to differentiate cytomegalovirus from HIV ulcers and begin appropriate therapy 8

Dietary Management of Eosinophilic Esophagitis (EoE)

1. Evidence‑Based Overview

• Dietary therapy is the only intervention that directly targets the underlying cause of EoE and can achieve drug‑free remission. 9

2. Step‑Up Elimination Strategy

*Starting with TFED and escalating only when histologic remission is not achieved reduces the number of required endoscopies by ≈20 % compared with initiating SFED. 10

3. Trigger Foods and Their Relative Frequency

• Primary triggers – most commonly implicated in EoE:

  • Cow’s milk (≈42 % of cases)
  • Wheat/gluten‑containing grains (≈10.9 %)
  • Eggs (≈21.5 %)
  • Sources: 9, 11

• Secondary triggers – considered if remission is not achieved with primary‑trigger elimination:

  • Soy and other legumes (≈8.4 %)
  • Peanuts and tree nuts (≈9.9 %)
  • Fish and shellfish (frequency reported but not quantified)
  • Sources: 9, 11

4. Mandatory Dietitian Involvement

• All elimination diets must be supervised by an experienced dietitian to prevent nutritional deficiencies, ensure adequate caloric and micronutrient intake, and monitor growth in children. 9, 10, 12
• Specific responsibilities include:
  
  • Routine growth monitoring for pediatric patients. 9, 10
  • Assessment of need for micronutrient supplementation (e.g., calcium, vitamin D). 9, 10
  • Screening for coeliac disease before removing wheat/gluten. 9, 10

5. Histologic Confirmation

• Endoscopic biopsy after 8–12 weeks of any elimination phase is required because ≈41 % of patients report symptomatic improvement without true histologic remission, risking ongoing inflammation and fibrosis. 11

6. Role of Allergy Testing and Formula Selection

• Skin prick, serum IgE, and patch testing have limited predictive value (≈45.5 % efficacy) and should not guide food elimination in EoE. 13, 14
• EoE is principally a non‑IgE‑mediated disorder. 14
• Only amino‑acid‑based elemental formulas are appropriate for refractory cases; polymeric or semi‑elemental formulas contain intact proteins and are ineffective. 14

7. Long‑Term Food Reintroduction

• Foods proven to trigger disease must remain excluded indefinitely; spontaneous tolerance is not expected. 12
• Systematic re‑introduction should be performed with repeat endoscopy and biopsy every 8–12 weeks to identify specific triggers. 9, 10

8. Psychosocial Considerations

• Discuss the psychological impact of restrictive diets (social isolation, anxiety, quality‑of‑life effects) with patients and families. 13
• Decision‑making should balance:
  
  • Patient motivation and lifestyle preferences. 10, 12
  • Family resources and support systems. 12
  • Willingness to undergo repeated endoscopic assessments. 13, 10
  • Risk of developing food aversions, especially in children. 9, 10

Management of Eosinophilic Esophagitis (EoE)

First‑Line Pharmacologic Therapy

• In adult and pediatric patients with confirmed EoE, an 8‑ to 12‑week trial of a proton‑pump inhibitor (e.g., omeprazole 20 mg twice daily) is recommended as an initial therapeutic option because it provides substantial clinical efficacy and has a favorable safety and cost profile. 15

• Recent comparative studies show that PPI‑responsive EoE is clinically, endoscopically, histologically, and molecularly indistinguishable from classic (non‑PPI‑responsive) EoE, supporting the use of PPIs as a true treatment rather than merely a diagnostic filter. 15

• The PPI trial should be regarded as a therapeutic intervention, not a diagnostic test to exclude EoE; treatment decisions should be based on therapeutic response rather than on the trial’s ability to “rule out” disease. 15

• Swallowed topical corticosteroids (fluticasone or budesonide formulations) are highly effective for inducing both histologic remission (eosinophil count < 15 eos/hpf) and clinical symptom improvement in patients with EoE. 16

• The American Gastroenterological Association issues a strong recommendation for topical corticosteroids as the preferred pharmacologic therapy for EoE, reflecting high‑quality evidence of benefit. 16

Endoscopic Monitoring

• A repeat upper endoscopy with esophageal biopsies after 8–12 weeks of any pharmacologic therapy (PPIs or topical steroids) is mandatory because patient‑reported symptom relief does not reliably predict histologic healing. 16

• Histologic response is defined as ≤ 15 eosinophils per high‑power field; achieving this threshold is essential to prevent ongoing inflammation and fibrosis. 16

• Clinicians must not equate symptomatic improvement with histologic remission; failure to confirm mucosal healing can allow persistent eosinophilic inflammation despite apparent clinical benefit. 16

Management of Esophagitis

GERD‑Related Erosive Esophagitis

• First‑line therapy: Initiate a proton‑pump inhibitor (PPI) at standard dose (e.g., omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, or rabeprazole 20 mg) once daily for 8 weeks. Healing rates exceed 80 % with this regimen. 17
• Comparative efficacy: PPIs are significantly more effective than H₂‑receptor antagonists, which in turn are superior to placebo for both endoscopic healing and symptom relief. [17][18]
• Extension of therapy: If endoscopic healing is incomplete after 8 weeks in adults, extend PPI treatment for an additional 8 weeks. 17
• Escalation strategy: For patients with inadequate response to once‑daily dosing, increase to twice‑daily PPI dosing before labeling treatment as a failure. 18
• Maintenance requirement: Continuous daily PPI therapy is mandatory after healing to prevent recurrence; without maintenance, recurrence rates approach 80 % within one year. 17
• On‑demand therapy: On‑demand or intermittent PPI dosing is not recommended for documented erosive disease because recurrence is unacceptably high compared with continuous daily therapy. 17
• Dose minimization: After achieving control, taper the maintenance dose to the lowest effective amount while maintaining daily administration. 17
• H₂‑antagonist role: H₂‑receptor antagonists are ineffective for long‑term maintenance and are no better than placebo in preventing recurrence. 17
• Adjunct nocturnal H₂RA: Adding a nocturnal H₂‑receptor antagonist to twice‑daily PPI therapy does not improve efficacy and should be avoided. 18
• Treatment failure definition: Patients whose heartburn persists despite twice‑daily PPI therapy should be considered treatment failures and undergo endoscopic evaluation. 18
• Lifestyle modification: Lifestyle measures (weight loss, head‑of‑bed elevation, avoiding late meals) should be individualized rather than universally prescribed. 18

Eosinophilic Esophagitis (EoE)

• First‑line pharmacologic options:
  
  • PPI regimen: Twice‑daily PPI (e.g., omeprazole 20–40 mg BID in adults; weight‑based dosing in children) for 8–12 weeks is recommended because of its safety, low cost, and substantial efficacy. 19
  • Topical corticosteroids: Swallowed fluticasone or budesonide are highly effective and carry a strong recommendation based on moderate‑quality evidence. 19
• Endoscopic monitoring: Perform repeat endoscopy with biopsies from multiple esophageal sites after 8–12 weeks of therapy while the patient remains on treatment; symptom improvement alone does not reliably indicate histologic healing. [20][19]
• Biopsy protocol: Obtain a minimum of six biopsies from different esophageal locations to assess response; histologic remission is defined as fewer than 15 eosinophils per high‑power field. 20
• Maintenance therapy: Continue the effective PPI or topical steroid indefinitely in patients who achieve histologic remission, as relapse rates are extremely high after drug withdrawal. 20
• Comparative durability: Limited data suggest PPIs may maintain sustained histologic response better than low‑dose topical steroids. 20
• Dietary therapy (supervised):
  
  • Six‑food elimination diet yields 72–79 % histologic remission but has lower patient acceptance.
  • Two‑food elimination (milk + wheat) achieves ~43 % remission with better adherence.
  • All elimination diets must be supervised by an experienced dietitian to avoid nutritional deficiencies, especially in children. [@‑]
• Allergy testing: Skin prick, serum IgE, and patch testing have limited predictive value (~45 % efficacy) and should not guide food elimination strategies. [@‑]
• Endoscopic dilation for strictures: In patients with dysphagia from EoE‑related strictures, perform conservative endoscopic dilation; it improves dysphagia in ~87 % of cases but does not treat underlying inflammation. 20
• Safety of dilation: Perforation occurs in ~0.4 % of procedures and hospitalization in ~1.2 %; most perforations were linked to more aggressive techniques used before 2009. 20
• Combined approach: Optimal outcomes are achieved by pairing dilation with anti‑inflammatory therapy (PPI or topical steroid). [@‑]
• Critical pitfall: Do not equate symptom resolution with histologic healing; about 41 % of patients report symptom improvement without true remission, underscoring the need for repeat endoscopic assessment. [@‑]

Infectious (Candidal) Esophagitis

• Systemic antifungal requirement: Effective treatment requires systemic antifungal therapy; topical agents are insufficient for esophageal disease. 21
• First‑line oral agent: Fluconazole administered orally for 14–21 days is the drug of choice because of high efficacy and excellent tolerability. 21
• Alternative oral agent: Itraconazole oral solution for 14–21 days is equally effective but less well tolerated. 21
• IV alternatives: Intravenous caspofungin or voriconazole are effective alternatives but are associated with higher relapse rates compared with fluconazole. 21
• Diagnostic trial: In patients with typical symptoms, a therapeutic trial of antifungal medication is appropriate before endoscopy; clinical response should be evident within 48–72 hours. 21

Evidence‑Based Management of Eosinophilic Esophagitis

Causes

• Aeroallergens may contribute to the development of eosinophilic esophagitis, suggesting an environmental trigger beyond food antigens. 22

Diagnostic and Monitoring Strategy

• After 8–12 weeks of any therapy, repeat upper endoscopy with biopsies from at least six distinct esophageal locations while the patient remains on treatment; this endoscopic assessment is essential because symptom improvement does not reliably indicate histologic healing (≈ 41 % of patients feel better despite persistent eosinophilia). 23
• Histologic remission is defined as fewer than 15 eosinophils per high‑power field (≈ 0.3 mm²). 23

Pharmacologic Therapy

First‑Line Proton‑Pump Inhibitor (PPI) Trial

• PPI‑responsive eosinophilic esophagitis is clinically, endoscopically, histologically, and molecularly indistinguishable from non‑PPI‑responsive disease, confirming that a positive response represents true eosinophilic esophagitis rather than isolated gastro‑esophageal reflux disease. 23

Second‑Line Topical Corticosteroids

• (No uniquely cited fact with a citation for efficacy beyond the PPI‑responsive statement; therefore omitted.)

Maintenance Therapy

• Ongoing maintenance with the effective PPI or swallowed topical corticosteroid is recommended indefinitely after achieving histologic remission to prevent recurrence of dysphagia, food impaction, and esophageal stricture formation. 22
• Limited evidence indicates that PPIs may be more effective than low‑dose topical steroids in sustaining histologic response over the long term. 22
• Patients who wish to avoid prolonged steroid exposure may consider discontinuing therapy after remission, provided they receive close clinical follow‑up and monitoring. 22

Dietary Management

• Allergy testing (skin prick, serum IgE, patch testing) has low predictive value (~45 % accuracy) and should not be used to direct food‑elimination strategies in eosinophilic esophagitis. [22][23]
• Supervised elimination diets require involvement of an experienced dietitian throughout both the elimination and re‑introduction phases to avoid nutritional deficiencies, ensure adequate micronutrient intake (e.g., calcium, vitamin D), and monitor growth in pediatric patients. 23

Key Clinical Pitfalls

• Symptom resolution alone does not confirm histologic healing; endoscopic reassessment is mandatory. 23
• Discontinuation of maintenance therapy after remission is discouraged unless the patient explicitly prioritizes avoiding long‑term medication and commits to rigorous follow‑up. 22
• Allergy testing should not guide dietary elimination because eosinophilic esophagitis is primarily a non‑IgE‑mediated disorder. [22][23]
• Coexisting gastro‑esophageal reflux disease and eosinophilic esophagitis are common; both conditions may need simultaneous treatment. 23